# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Pote...
Morphic Holding (NASDAQ:MORF) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(0.9...
Canaccord Genuity analyst Edward Nash maintains Morphic Holding (NASDAQ:MORF) with a Buy and lowers the price target from $6...
Citigroup analyst Samantha Semenkow initiates coverage on Morphic Holding (NASDAQ:MORF) with a Buy rating and announces Pric...
Morphic Holding (NASDAQ:MORF) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.9...
-SEC 8K Filing